Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals, Inc. Chief Operating Officer Seshadri Neervannan reported equity compensation activity tied to restricted stock units. On March 15, 2026, vested RSUs were settled into 26,287 shares of common stock at an exercise price of $0.00 per share.
The RSUs were granted under the Tarsus 2020 Stock Plan across awards from 2022 through 2025, each vesting in four annual 25% installments on March 15, subject to continuous service. After these settlements, Neervannan directly holds 97,104 shares of common stock.
The filing also shows 475 shares of common stock held indirectly by his daughter, with an explicit disclaimer that he does not beneficially own those securities for Section 16 or other purposes.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala acquired 26,482 shares of common stock on March 15, 2026 through the settlement of vested Restricted Stock Units granted under the company’s 2020 Stock Plan. Each RSU converts into one share of common stock at no cash exercise price.
Following these transactions, Mottiwala directly holds 74,536 shares of Tarsus common stock. This total includes 497 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, reflecting ongoing equity-based compensation rather than open-market buying or selling.
Tarsus Pharmaceuticals, Inc. officer Jeffrey S. Farrow reported the settlement of vested Restricted Stock Units into common stock. On March 15, 2026, he acquired 13,042 shares of common stock upon exercise/settlement of RSUs granted under the company’s 2020 Stock Plan.
The filing indicates these RSUs were from grants made on March 7, 2024 and March 5, 2025, each vesting in four equal annual installments every March 15, subject to continued service. Following these transactions, Farrow directly holds 49,746 shares of Tarsus common stock.
Tarsus Pharmaceuticals, Inc. reported that President/CEO and Board Chair Bobak R. Azamian exercised and settled restricted stock units into common shares. On March 15, 2026, he converted RSUs covering 66,274 shares of common stock at a conversion price of $0.00 per share.
After these settlements, his directly held common stock position reported in this filing is 68,024 shares. He also has an indirect holding of 857,991 common shares through the Bobak Azamian Living Trust established April 16, 2018, where he has voting and dispositive power over the shares.
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu acquired shares through the vesting and settlement of Restricted Stock Units (RSUs). On March 15, 2026, 2,511 RSUs were settled into 2,511 shares of common stock at a conversion price of $0.00 per share.
Following these transactions, she held 7,534 RSUs and 24,452 shares of common stock directly. She also had indirect ownership of 6,360 common shares through a spouse’s Roth IRA and 12,040 common shares through a 401(k) plan.
According to the RSU grant terms, awarded on March 5, 2025 under the 2020 Stock Plan, 25% of the RSUs vest on March 15 of each of 2026, 2027, 2028 and 2029, subject to her continuous service.
TARS submitted a Form 144 notice reporting an intended sale of 3,125 shares of Common Stock tied to restricted stock vesting on 03/16/2026, with a listed dollar amount of $216,920.94. The filing also records a prior sale of 8,366 shares on 03/04/2026 by Seshadri Neervannan with a listed dollar amount of $641,421.22. The broker listed is Fidelity Brokerage Services LLC (address shown) and the trading venue is NASDAQ.
TARS filed a Form 144 notice for the sale of 4,029 shares of Common Stock. The filing lists the sale tied to a restricted stock vesting event dated 03/16/2026. The excerpt also shows a prior disposition of 15,565 shares by Dianne C. Whitfield on 01/02/2026.
This Form 144 is a routine Section 144 notice of proposed resale; the filing lists the broker as Fidelity Brokerage Services LLC and identifies the transaction as related to compensation vesting.